pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 4·1 min read
save

Ambient scribing startups draw attention as Abridge secures $300 million funding

Aug 4, 2026·read at Endpoints ↗DealNeutral

Last summer, a wave of ambient scribing startups captured the health-tech spotlight.

These companies employ artificial-intelligence systems that listen to doctor-patient conversations and automatically generate clinical notes.

Among them, Abridge announced a $300 million Series funding round, underscoring investor interest in the technology.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “The great ambient scribe convergence”

read at Endpoints ↗
79 words · retrieved Aug 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoAll 50 states sign up for most favored nation prices under Medicaid, Trump saysEndpoints
  • 3h agoFDA approves Lilly's oral SERD combo for second-line breast cancer therapyEndpoints
  • 5h agoPost-Hoc Live: The China Biotech Debate goes to WashingtonEndpoints
  • 6h agoCHMP backs Novo’s hemophilia A drug and seven other medicinesEndpoints
  • 6h agoFDA says initial rejections of new drugs have declinedEndpoints